


IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Attorney Docket No.: MGU0036US.NP
Inventors: Kubow et al.
Serial No.: 10/591,481
Filing Date: Not Assigned
Examiner: Not Assigned
Customer No.: 26259
Group Art Unit: Not Assigned
Confirmation No.: Not Assigned
Title: Compositions and Methods for Preventing
or Treating an Inflammatory Response

I, Jane Massey Licata, Registration No. 32,257,
certify that this correspondence is being deposited
with the U.S. Postal Service as First Class mail in
an envelope addressed to the Commissioner for Patents
P.O. Box 1450, Alexandria, VA 22313-1450

On this date: November 27, 2006


Jane Massey Licata, Registration No. 32,257

Commissioner for Patents
P.O. Box 1450
Alexandria, VA 22313-1450

Sir:

INFORMATION DISCLOSURE STATEMENT

Pursuant to 37 C.F.R. §1.56 and in accordance with 37 C.F.R. §§1.97-1.98, information relating to the above-identified application is hereby disclosed. Inclusion of information in this statement is not to be construed as an admission that this information is material as that term is defined in 37 C.F.R. §1.56(b).

(XX) In accordance with §1.97(b), since this Information Disclosure Statement is being filed either within three months of the filing date of the above-identified application, within three months of the date of entry into the national stage of the above identified application as set forth in §1.491, or before the mailing date of a first Office Action on the merits of the above-identified application, no additional fee is required.

() In accordance with §1.97(c), this Information Disclosure Statement is being filed after the period set forth in §1.97(b) above but before the mailing date of either a Final Action under §1.113 or a Notice of Allowance under §1.311, therefore:

() Certification in Accordance with §1.97(e) is attached hereto; or

() Authorization to charge Deposit Account No. 50-1619 the fee of \$180.00 as set forth in §1.17(p) is provided.

() In accordance with §1.97(d), this Information Disclosure Statement is being filed after the mailing date of either a Final Action under §1.113 or a Notice of Allowance under §1.311 but before the payment of the Issue Fee, therefore included are: Certification in Accordance with §1.97(e); Petition Requesting Consideration of the Information Disclosure Statement; and the fee of \$130.00 as set forth in §1.17(I) (1).

(XX) Copies of each of the references listed on the attached Form PTO-1449 (modified) are enclosed herewith with the exception of U.S. Patents and U.S. Published Applications.

() In accordance with §1.98(d), copies of some or all of the references listed on the attached Form PTO-1449 (modified) are not enclosed herewith because they were previously submitted to the U.S. Patent and Trademark Office in prior application Serial No. _____, filed _____, for which a claim for priority under 35 U.S.C. §120 has been made in the instant application.

Please charge any deficiency or credit any overpayment to Deposit Account No. 50-1619. This form is submitted in duplicate.

() The relevance of the listed references in a foreign language is as stated in the specification at pages @@.

(XX) All listed references are in the English language.

Respectfully submitted,



Jane Massey Licata
Registration No. 32,257

Date: November 27, 2006

Licata & Tyrrell P.C.
66 E. Main Street
Marlton, New Jersey 08053

(856) 810-1515

Form PTO-1449 Modified List of Patents and Publications Cited by Applicant (Use several sheets if necessary) U.S. Department of Commerce		Docket No. MGU0036US.NP	Serial No. 10/591,481
		Applicant Kubow et al.	
		Filing Date Not Assigned	Group Not Assigned
OTHER DOCUMENTS (Including Author, Title, Date, Pertinent Pages, Etc.)			
	AA	Chan et al., "Ceramide Path in Human Lung Cell Death", Am. J. Respir. Cell Mol. Biol. 2000 22:460-468	
	AB	Erdreich-Epstein, "Ceramide Signaling in Fenretinide-induced Endothelial Cell Apoptosis", J. Biol. Chem. 2002 277(51):49531-49537	
	AC	Hannun et al., "Functions of Sphingolipids and Sphingolipid Breakdown Products in Cellular Regulation", Science 1989 243:500-507	
	AD	Lavrentiadou et al., "Ceramide-Mediated Apoptosis in Lung Epithelial Cells Is Regulated by Glutathione", Am. J. Respir. Cell Mol. Biol. 2001 25:676-684	
	AE	Liu et al., "Glutathione Regulation of Neutral Sphingomyelinase in Tumor Necrosis Factor- α -induced Cell Death", J. Biol. Chem. 1998 273(18):11313-11320	
	AF	Luberto et al., "Differential Effects of Sphingomyelin Hydrolysis and Resynthesis on the Activation of NF- κ B in Normal and SV40-transformed Human Fibroblasts", J. Biol. Chem. 2000 275(19):14760-14766	
	AG	Maurer et al., "Increase of Ceramide and Induction of Mixed Apoptosis/Necrosis by N-(4-Hydroxyphenyl)-retinamide in Neuroblastoma Cell Lines", J. National Cancer Institute 1999 91(13):1138-1146	
EXAMINER		DATE CONSIDERED	

Form PTO-1449 Modified List of Patents and Publications Cited by Applicant (Use several sheets if necessary) U.S. Department of Commerce	Docket No. MGU0036US.NP	Serial No. 10/591,481
	Applicant Kubow et al.	
	Filing Date Not Assigned	Group Not Assigned

U. S. PATENT DOCUMENTS

Examiner Initial		Document No.	Date	Name	Class	Subclass

FOREIGN PATENT DOCUMENTS

Examiner Initial		Document No.	Date	Country	Translation YES NO	
	BA	CA 2 365 290	9-8-00	Canada	x	
	BB	WO 2004/064823	8-5-04	PCT	x	
	BC	WO 00/00207	1-6-00	PCT	x	

EXAMINER

DATE CONSIDERED